AFP and neoplasm: As for the role of more aggressive neoadjuvant strategies in preoperatively identifying high-risk patients, a prospective US study showed that two tumor markers (PIVKA and AFP-L3) identified patients with an unacceptable post-LT recurrence risk, who may benefit from intensified loco-regional or systemic therapy pre-transplant [34].